- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04723888
Alpha-Ketoglutarate and Abdominal Aortic Aneurysm Progression and Rupture
The Intervention Effect Of Alpha-Ketoglutarate On Abdominal Aortic Aneurysm Progression and Rupture: A Prospective, Randomized Parallel Controlled Study Based On Large Cohorts
Study Overview
Status
Intervention / Treatment
Detailed Description
Abdominal aortic aneurysm (AAA) is an age-related disease that characterized by permanent regional dilation of the abdominal aortae, which results in catastrophic event of rupture and sudden death. Currently, no effective drug to limit the progression or reduce the risk of rupture has been developed.
Metabolic pathways, including glucose metabolism, lipid metabolism, and amino acid metabolism, have indispensable roles in normal and dysfunctional vasculature. The Krebs cycle is responsible for obtaining energy from food in the form of ATP, and ATP is essential for muscle contraction and correct functioning of all organs. Besides, tight control of mitochondrial functions is critical for maintaining metabolism balance.
As an important metabolite in Krebs cycle, alpha-ketoglutarate not only improved energy metabolism, but also extended lifespan and reduced morbidity in aging mice. It is widely used in the market as a nutritional supplement specially by athletes to increase muscle strength. Until now, no obvious toxic and side effects to the body was observed. Given the high bioavailability, we propose that dietary supplementation with alpha-ketoglutarate can improve the outcome in patients with an abdominal aortic aneurysm of 39-49 mm in diameter.
Therefore, the project team intends to establish the abdominal aortic aneurysm rupture risk prediction model in the elderly cohort in the early stage, and randomize groups in patients with an abdominal aortic aneurysm of 39-49 mm in diameter based on whether or not to supplement alpha-ketoglutarate. There are two cohorts: the alpha-ketoglutarate intervention cohort and the parallel control cohort. By observing the efficacy in terms of change in aortic diameter and abdominal aortic aneurysm rupture incidence in the two groups during the follow-up period, it provides evidence-based medical evidence for the future clinical application of alpha-ketoglutarate.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Shanghai, China
- Recruiting
- Cardiology, Ren Ji Hospital
-
Contact:
- Jun Pu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Presence of an infrarenal AAA with a maximum diameter of 39-49 mm;
- Han nationality;
- Between 50 years or more, no gender limit;
- No mental illness;
- No history of supplement allergy or supplement allergy;
- Subjects voluntarily participate in this study, sign an informed consent form, have good compliance, and cooperate with follow-up.
Exclusion Criteria:
- Previous infrarenal aortic surgery;
- Planned major surgery;
- Known aortic dissection;
- Have received any other clinical trial treatment within 1 year;
- Systemic treatment with corticosteroids or other systemic immunomodulatory therapy;
- Severe infections, including but not limited to infections requiring hospitalization, bacteremia, severe pneumonia, etc.;
- Known or suspected inherited connective tissue disorder;
- Calculated creatinine clearance of less than 30 ml/min;
- Known significant liver disease;
- Known human immunodeficiency virus infection at the time of screening;
- Serious concomitant illness associated with life expectancy of less than 2 years;
- Any other significant and unstable condition that could limit compliance with the trial protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: alpha-ketoglutarate Group
Take alpha-ketoglutarate supplements, alpha-ketoglutarate 300mg/d mixed with food or drink, for 1 years
|
alpha-ketoglutarate supplements
|
No Intervention: Normal Control Group
Don't take alpha-ketoglutarate supplements
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in aortic diameter
Time Frame: 1 year
|
Measure the aortic diameter by ultrasound imaging from leading edge adventitia at the anterior wall to leading edge adventitia at the posterior wall.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rates of AAA repair/rupture
Time Frame: 1 year
|
Calculate the incidence of AAA repair/rupture
|
1 year
|
Rates of mortality
Time Frame: 1 year
|
Calculate the mortality due to AAA rupture
|
1 year
|
Changes level of plasma biomarker
Time Frame: 1 year
|
Measure plasma levels of tryptase
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jun Pu, Renji Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AKG Intervention study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on alpha-ketoglutarate
-
Robert Bok, MD, PhDNational Cancer Institute (NCI)RecruitingAdult Gliomas, MixedUnited States
-
National Cardiovascular Center Harapan Kita Hospital...Unknown
-
Nicola LongoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Completed
-
Ain Shams UniversityCompletedCardioplegia Solution Adverse ReactionEgypt
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular DiseaseUnited States
-
University of California, Los AngelesCompleted
-
Marc Sakwa, MDEssential Pharmaceuticals, LLCCompletedMyocardial Ischemia | Heart Diseases | Coronary Artery Disease | Coronary Disease | Valvular Heart DiseaseUnited States
-
Children's Hospital Medical Center, CincinnatiEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingAutism Spectrum Disorder | Autistic Disorder | Fragile X Syndrome | Asperger SyndromeUnited States
-
Christina Murphey, RN, PhDTerminatedDepression | Insomnia | Anxiety | Sleep QualityUnited States
-
Christina Murphey, RN, PhDSuspended